Introduction
Obstructive sleep apnea (OSA) represents a highly prevalent sleep disorder characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, resulting in oxygen desaturation, arousals, and sleep fragmentation. Despite affecting an estimated 936 million adults worldwide, OSA remains substantially underdiagnosed, with approximately 80% of moderate-to-severe cases remaining undetected in clinical practice.
The consequences of untreated OSA extend far beyond sleep disruption. Patients with OSA experience increased incidence of hypertension, myocardial infarction, stroke, atrial fibrillation, and sudden cardiac death. Additionally, daytime somnolence, cognitive impairment, and mood disorders significantly impact quality of life, occupational performance, and public safety. Understanding OSA pathophysiology, recognizing clinical presentation, and identifying patients for diagnostic evaluation represent essential competencies for healthcare providers across specialties.
OSA Pathophysiology and Airway Collapse
During wakefulness, upper airway patency is maintained through continuous contraction of pharyngeal dilator muscles, including the genioglossus, soft palate muscles, and pharyngeal constrictor muscles. These muscles are innervated primarily by the hypoglossal nerve (cranial nerve XII) and receive tonic activity throughout wakefulness.
During sleep, muscle tone systematically decreases across skeletal muscles. Pharyngeal dilator muscles also experience reduced tone during non-rapid eye movement sleep and even more pronounced reductions during rapid eye movement (REM) sleep. This physiological reduction in airway muscle tone predisposes to airway narrowing and obstruction in predisposed individuals.
Airway obstruction occurs when the collapsing pressure exceeds the pharyngeal muscle dilating pressure. The airway collapse typically occurs at the level of the oropharynx, at or posterior to the soft palate. The tongue base is pushed posteriorly, narrowing the airway lumen. This obstruction results in cessation of airflow (apnea) or significant airflow reduction (hypopnea), leading to oxygen desaturation.
The apnea-hypopnea index (AHI), defined as the number of apneas and hypopneas occurring per hour of sleep, stratifies disease severity. Mild OSA is defined as AHI 5-14 events/hour, moderate as AHI 15-29 events/hour, and severe as AHI >30 events/hour. Each obstructive episode typically continues 10-60 seconds before arousal occurs, restorative pharyngeal muscle tone returns, and breathing resumes.
Upper Airway Anatomy and Predisposing Factors
Multiple anatomical factors contribute to OSA susceptibility and severity. Anatomical assessment incorporates both skeletal structures and soft tissue characteristics.
Skeletal anatomy significantly influences airway dimensions and collapsibility. Retrognathia (posterior mandibular position), micrognathia (small mandible), maxillary retrusion, and increased cranial base angle all reduce the sagittal dimension of the oropharynx, predisposing to obstruction. These skeletal characteristics frequently manifest in patients with OSA when compared to matched controls.
Soft tissue factors include tonsillar hypertrophy, adenoidal enlargement, uvular edema, and soft palate thickening. Enlarged tonsils and adenoids physically narrow the oropharyngeal airway lumen. Soft palate and uvular characteristics influence airway collapsibility through effects on tissue mass and mechanical compliance.
Neck circumference represents one of the most robust anthropometric predictors of OSA. Increased subcutaneous and visceral fat in the neck region adds mass surrounding the pharyngeal airway, increasing collapsibility. Neck circumference correlates strongly with OSA severity in both men and women.
Body mass index (BMI) demonstrates a dose-dependent relationship with OSA prevalence. Each unit increase in BMI increases OSA odds by approximately 10%. Weight gain among previously non-apneic individuals frequently precipitates OSA onset. Conversely, significant weight loss substantially improves or resolves OSA in many patients.
Mallampati Scoring and Clinical Assessment
The modified Mallampati scoring system, originally developed to predict difficult intubation, has been adapted to assess oropharyngeal airway space and correlates with OSA risk. The classification system evaluates soft palate, uvula, and tonsillar visibility when the mouth is opened and tongue is fully protruded.
Mallampati Class I (soft palate, uvula, and anterior and posterior tonsillar pillars visible) represents the most open airway and lowest OSA risk. Mallampati Class IV (soft palate not visible, only the base of the tongue visible) represents the most narrowed airway with highest OSA risk.
Mallampati scoring performs best when combined with assessment of other anatomical features, including tonsillar size, uvular position, lateral pharyngeal wall narrowing, and palatal height. Comprehensive oropharyngeal evaluation by trained clinicians enables prediction of OSA likelihood with moderate accuracy.
Risk Factors and Population Characteristics
Age represents a consistent OSA risk factor, with disease prevalence increasing progressively from young adulthood through older age. However, OSA can develop at any adult age and increasingly affects younger populations in association with obesity epidemics.
Male gender confers approximately 2-4 fold increased OSA risk compared to premenopausal women. However, postmenopausal women demonstrate OSA prevalence approaching that of men, suggesting hormonal factors modulate OSA risk. Sleep apnea in women is frequently underdiagnosed due to different symptom presentations and clinical recognition bias.
Menopause and postmenopausal hormone status influence OSA risk. Studies demonstrate increased OSA prevalence in postmenopausal women compared to premenopausal women, with hormone replacement therapy providing some protective effect.
Obesity, particularly central obesity with increased neck circumference, substantially increases OSA risk. The mechanical compression of the pharyngeal airway from increased neck fat mass, combined with reduced plasma volume and altered control of breathing, creates a high-risk phenotype.
Nasal obstruction, chronic rhinitis, and deviated septum contribute to increased upper airway resistance and can precipitate or exacerbate OSA. Nasal polyps and other nasal pathology similarly increase OSA risk.
Hypothyroidism, polycystic ovary syndrome, and acromegaly all increase OSA prevalence. These conditions involve tissue changes, metabolic alterations, or growth abnormalities that predispose to airway obstruction.
Cardiovascular and Metabolic Consequences
The cardiovascular consequences of untreated OSA are substantial and well-established. Recurrent oxygen desaturation episodes activate sympathetic nervous system activity, leading to increases in blood pressure, heart rate, and myocardial oxygen demand. These acute responses, when repeated hundreds of times nightly, produce chronic sympathetic activation and sustained hypertension.
Sleep fragmentation and intermittent hypoxia activate inflammatory pathways, with elevation of pro-inflammatory cytokines, C-reactive protein, and oxidative stress markers. This systemic inflammation contributes to vascular endothelial dysfunction and atherosclerotic progression.
Atrial fibrillation develops with increased frequency in OSA patients, with disease severity correlating with arrhythmia prevalence. The arrhythmogenic mechanisms involve sympathetic nervous system activation, hypoxia-induced cardiac irritability, and atrial remodeling from hemodynamic stress.
Myocardial infarction and stroke risks are substantially elevated in OSA patients, even after adjustment for traditional cardiovascular risk factors. Sudden cardiac death rates increase substantially in severe OSA, particularly during sleep when patients are most vulnerable.
STOP-Bang Screening Questionnaire
The STOP-Bang questionnaire represents a practical, efficient screening tool for OSA identification in clinical practice. This eight-item questionnaire addresses common OSA symptoms and risk factors.
The STOP component evaluates Snoring (loud snoring), Tiredness (daytime somnolence), Observed apnea (witnessed breathing pauses), and high blood Pressure (hypertension diagnosis). The Bang component assesses BMI >30 kg/m², Age >50 years, Neck circumference, and Gender (male).
Patients responding affirmatively to ≥3 items have high OSA risk and warrant formal diagnostic evaluation. The questionnaire demonstrates sensitivity of 65-96% for moderate-to-severe OSA detection, depending on the cut-off score applied. Its brevity and ease of administration facilitate integration into routine clinical practice.
Daytime Symptomatology and Quality of Life
The Epworth Sleepiness Scale (ESS) quantifies daytime somnolence through patient self-report of sleep likelihood during eight common situations. The 24-point scale demonstrates reasonable correlation with objective sleepiness measures and correlates with OSA severity.
However, numerous OSA patients report minimal daytime somnolence despite severe disease. These "non-sleepy" apneics may present with other symptoms including nocturia, morning headaches, mood disturbance, or cognitive impairment. Absence of reported somnolence should not exclude OSA from diagnostic consideration.
Quality of life impairment in OSA extends beyond daytime somnolence. Patients frequently report reduced occupational performance, interpersonal relationship strain, sexual dysfunction, and mood disturbance. These domains of dysfunction persist even when objective sleepiness measures appear mild, highlighting the multifaceted impact of sleep apnea on wellbeing.
Conclusion
Obstructive sleep apnea results from complex interactions between anatomical predisposition, neuromuscular factors, and physiological characteristics. Understanding pathophysiology enables recognition of risk factors and identification of patients requiring diagnostic evaluation. Screening through tools such as the STOP-Bang questionnaire enables efficient identification of high-risk patients. Recognition of the diverse clinical presentations of OSA beyond daytime somnolence ensures that symptomatic patients receive appropriate evaluation and treatment, reducing the substantial morbidity and mortality associated with untreated disease.